[IL2106] Cyclin-K Degrader for Solid Tumors 

• Potentially first-in-class, orally available, small molecule Cyclin-K Degrader with strong anti-cancer activities for difficult cancers including those without identifiable drivers. 

• We are developing a potent Cyclin-K Degrader (through CDK 12 binding) which can be used for cancers without known drivers including HER2-negative gastric cancer, HER2-negative TNBC, colorectal cancer, etc.

• The lead candidate acts as a Cyclin-K molecular glue, a highly promising type of targeted protein degradation (TPD) and has a potential to be developed as an intermittent oral monotherapy.

• The lead candidate has exhibited potent growth inhibition in various cancer cells (induced significant tumor regression in the HER2-negative metastatic gastric cancer and triple-negative breast cancer in vivo models.

•  This candidate is ready for IND-enabling GLP toxicity studies.